P3

P3 Health Partners to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

Retrieved on: 
Friday, March 15, 2024
Managed Care, General Health, Health, Practice Management, Webcast, Medicare, P3

The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call.

Key Points: 
  • The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call.
  • We are reaffirming our 2024 guidance based on stable utilization trends in early 2024 relative to prior periods.
  • We continue to have confidence in our current estimates of medical expenses for the full year 2024.
  • Further, we observed strong membership growth in early 2024 to a total of approximately 121,000 Medicare risk members from 108,900 at year end 2023.

P3 Health Partners to Present at the BTIG Digital Health Forum

Retrieved on: 
Thursday, November 16, 2023
Managed Care, General Health, Health, Practice Management, Life Partners, Inc., PIII, Pharmaceutical industry, P3

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that leadership will participate in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Dr. Sherif Abdou, Chief Executive Officer and Co-founder of P3, at 12:00 p.m. PT/3:00 p.m.

Key Points: 
  • P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced that leadership will participate in the BTIG Digital Health Forum, being held virtually, on Monday, November 20, 2023, including a panel discussion with Dr. Sherif Abdou, Chief Executive Officer and Co-founder of P3, at 12:00 p.m. PT/3:00 p.m.
  • ET.

Graham Corporation Acquires P3 Technologies to Expand Turbomachinery Capabilities and Technology Solutions

Retrieved on: 
Friday, November 10, 2023
Aerospace, Manufacturing, Defense, Maritime, Transport, Other Defense, Contracts, Other Energy, Utilities, Oil, Gas, Alternative Energy, Energy, Other Manufacturing, Steel, Nuclear, Engineering, Machine Tools, Metalworking & Metallurgy, Chemicals, Plastics, EBITDA, Acquisition, NYSE, Hydrogen, Corporation, SCAMP, GHM, Nitrogen, MCD, Methane, Oxygen, Growth, P3, Jupiter

With an experienced team of highly skilled gas-turbine engineers, P3’s development process results in innovative solutions to complex technical challenges.

Key Points: 
  • With an experienced team of highly skilled gas-turbine engineers, P3’s development process results in innovative solutions to complex technical challenges.
  • P3 is an ideal bolt on business and brings highly complementary technology that enhances and expands our turbomachinery solutions.
  • Importantly, P3 also is bringing unique intellectual property that we believe we can leverage to expand the market potential of the business.
  • In addition, P3 has created robust turbomachinery development tools which enable efficient design iteration cycles reducing lead times to product launches for customers.

HealthEdge Partners with P3 Oral Surgery to Build Leading Oral Surgery Platform

Retrieved on: 
Monday, December 4, 2023
McGuireWoods, Chicago Growth Partners, LLP, Surgeon, OSO, Partnership, Growth, Health, Mid-Atlantic (United States), Dentistry, P3

TAMPA, Fla., Dec. 4, 2023 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge") announced it has partnered with Pluri Potent Partnership, LLC ("P3 Oral Surgery", "P3", or the "Company") an oral surgery service organization to build a leading Oral Surgery Services Organization ("OSO") in the Mid-Atlantic region.

Key Points: 
  • TAMPA, Fla., Dec. 4, 2023 /PRNewswire/ -- HealthEdge Investment Partners, LLC ("HealthEdge") announced it has partnered with Pluri Potent Partnership, LLC ("P3 Oral Surgery", "P3", or the "Company") an oral surgery service organization to build a leading Oral Surgery Services Organization ("OSO") in the Mid-Atlantic region.
  • The practices represent a mature, fully integrated oral and maxillofacial surgery platform offering a full spectrum of oral surgery services, including extractions, implants, and cosmetic oral and maxillofacial procedures.
  • HealthEdge Partner Scott Heberlein commented "We are thrilled to announce this strategic investment in P3 Oral Surgery.
  • We believe this investment will enable P3 to build on its market leading position in the Mid-Atlantic region by continuing to partner with elite oral surgeons.

P3 Health Partners Announces Third-Quarter and Year-to-Date 2023 Results

Retrieved on: 
Wednesday, November 8, 2023
Managed Care, Health, Adjustment, PMPM, Medicine, EBITDA, Life Partners, Inc., Patient, PIII, Pharmaceutical industry, Cryptocurrency, P3

P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the third quarter ended September 30, 2023.
  • “Our results for the third quarter show the continued improvement of the business as providers and patients mature on our platform.
  • All key metrics are tracking as expected and net cash used in operating activities has improved to negative $8 million for the quarter.
  • We are re-affirming our existing full-year 2023 guidance and providing preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million,” said Dr. Sherif Abdou, CEO of P3.

P3 Health Partners Schedules Third-Quarter 2023 Earnings Release and Conference Call

Retrieved on: 
Friday, November 3, 2023
General Health, Other Health, Health, Practice Management, Managed Care, P3, Webcast, Cryptocurrency, Financial adviser

The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website ( ir.p3hp.org ).

Key Points: 
  • The conference call will also be webcast live in the "Events & Presentations" section of the Investor page of the P3 website ( ir.p3hp.org ).
  • The Company’s press release will be available on the Investor page of P3’s website in advance of the conference call.
  • An archived recording of the webcast will be available on the Investor page of P3’s website for a period of 90 days following the conference call.

P3 Technologies Secures $10 Million Investment and Expands Footprint in Miami with Acquisition of Pet Pharmacy

Retrieved on: 
Thursday, October 19, 2023
Pharmacy, Insurance, Clarke, Contour, Pet, Acquisition, Prescription, Brandless, Overalls, Parent, Drug, Management, Medical imaging, P3T, P3

This infusion of capital will empower P3 Technologies to accelerate its mission of reshaping the pet healthcare landscape with technology-driven solutions and comprehensive pet care services tailored to the local market and beyond.

Key Points: 
  • This infusion of capital will empower P3 Technologies to accelerate its mission of reshaping the pet healthcare landscape with technology-driven solutions and comprehensive pet care services tailored to the local market and beyond.
  • In addition to the investment, P3 Technologies has acquired Heartland Veterinary Pharmacy and VetApproved Pharmacy, two well-established pet pharmacies strategically aligned with P3T's pet-first values.
  • P3 Technologies is a forward-thinking technology solutions provider committed to revolutionizing the pet health industry through innovative technology, patient-centric pet care, and strategic acquisitions.
  • By integrating cutting-edge technology with personalized services, P3 Technologies is redefining the way pet parents, pet insurers, and veterinarians access and receive medical care.

P3 Technologies Secures $10 Million Investment and Acquires Pet Pharmacy

Retrieved on: 
Wednesday, October 11, 2023
Pharmacy, Parent, Diversified Pharmaceutical Services, P3, Growth, Insurance, Acquisition, Prescription, Health, Medical imaging

The $10 million investment comes from a group of strategic investors who recognize P3T's innovative approach to pet healthcare delivery and its commitment to improving patient outcomes.

Key Points: 
  • The $10 million investment comes from a group of strategic investors who recognize P3T's innovative approach to pet healthcare delivery and its commitment to improving patient outcomes.
  • This influx of capital will enable P3 Technologies to accelerate its mission of transforming the healthcare industry through technology-driven solutions and comprehensive patient care services.
  • This investment reaffirms our dedication to enhancing the pet health experience for both pet parents and their providers."
  • In addition to the investment, P3 Technologies has acquired Heartland Veterinary Pharmacy  and VetApproved Pharmacy.

Corbion launches AlgaPrime™ DHA P3, addressing the demand for sustainable active nutrition in the pet food industry

Retrieved on: 
Monday, September 25, 2023
P3, Animal nutritionist, Climate change, Environment, DHA, Carbon, Pet, Dietary supplement, Bottled water

Corbion launches AlgaPrime™ DHA P3, addressing the demand for sustainable active nutrition in the pet food industry

Key Points: 
  • Corbion launches AlgaPrime™ DHA P3, addressing the demand for sustainable active nutrition in the pet food industry
    AlgaPrime™ DHA P3 offers pet food manufacturers higher levels of DHA while reducing dependency on scarce traditional omega-3 sources.
  • Produced via microalgae precision fermentation, AlgaPrime™ DHA P3 helps meet increasing consumer demand for more sustainable pet food ingredients, as nearly 70% of pet owners worldwide express concern about nutrition, climate change and a desire to make a positive impact on the environment through their everyday actions.
  • AlgaPrime™ DHA P3 is suitable for dry, wet, and injection-mold applications, allowing efficient access to, and use of, long-chain omega-3s.
  • “The launch of AlgaPrime™ DHA P3 furthers Corbion’s mission to preserve what matters by offering sustainable ingredients for healthier people, pets, and the planet,” said Tim Rutten, Vice President at Corbion Algae Ingredients.

MedReview Chief Strategy Officer to Speak at Prestigious HPRI East Conference

Retrieved on: 
Wednesday, August 30, 2023
Senior, Data mining, Population Health Management, Classification, Colonnaded Street, Wilson, P3, Population health, DRG, Roger Hawkins (drummer), Cryptocurrency

NEW YORK, Aug. 30, 2023 /PRNewswire-PRWeb/ -- MedReview, Inc., a leading provider of payment integrity, utilization management, and quality surveillance services, today announced that Chief Strategy Officer Kathy Gonzales has been selected as a featured presenter at the Healthcare Payment and Revenue Integrity Congress (HPRI) East. Gonzales will be joined by Timothy Wilson, Senior Vice President of Population Health Management at P3 Health Partners, a MedReview client, and MedReview data mining expert Michael Brown for a presentation titled "Better Manage What You Are Missing: Collaborate with Data Mining Expertise." The presentation will take place Sept. 14 at 11:30 at The Colonnade in Boston.

Key Points: 
  • Chief Strategy Officer Kathy Gonzales has been selected as a featured presenter at the Healthcare Payment and Revenue Integrity Congress (HPRI) East.
  • NEW YORK, Aug. 30, 2023 /PRNewswire-PRWeb/ -- MedReview, Inc., a leading provider of payment integrity, utilization management, and quality surveillance services, today announced that Chief Strategy Officer Kathy Gonzales has been selected as a featured presenter at the Healthcare Payment and Revenue Integrity Congress (HPRI) East.
  • "We're excited to share our story at HPRI East so that other companies can see a path to the results we have discovered."
  • HPRI East connects leading figures in payment integrity and revenue cycle management and is the only conference focusing on breaking down payor and provider silos.